ArticleAnnals of medicine2026
External validation of the MOG-AR score in pediatric myelin oligodendrocyte glycoprotein antibody-associated disease.
Article in Annals of medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPredicting the risk of relapse in myelin oligodendrocyte glycoprotein antibody-associated disease is essential for guiding early treatment decisions. A score evaluating onset age, sex, attack phenotype, and treatment received (MOG-AR) has been proposed to identify patients at high relapse risk since disease onset, but has never been validated in a pediatric population. This study aimed to externally validate the MOG-AR score in an exclusively pediatric cohort. PATIENTS AND
methodsWe retrospectively identified 139 children with myelin oligodendrocyte glycoprotein antibody-associated disease (age <18 years) within the past decade. The MOG-AR score was calculated and the patients were stratified into four risk grades. Discrimination and calibration were assessed using multiple complementary metrics, and univariable analyses were performed for each score component. Sensitivity analyses included exploratory reclassification using modified MOG-AR grade thresholds and the development of an exploratory phenotype-based model.
resultsWe included 139 children with a median follow-up of 43 months; relapse occurred in 28.8% of patients. Harrell's concordance index was 0.472 (95% confidence interval, 0.366-0.577), and the time-dependent area under the receiver operating characteristic curve ranged from 0.467 to 0.510 over 1-5 years. Calibration assessment indicated limited variation in predicted probabilities across risk grades. Modified MOG-AR grade thresholds did not improve risk group separation (log-rank
conclusionsIn this single-center pediatric cohort, the MOG-AR score did not provide clinically useful stratification of first-relapse risk. Limited variability in the age and treatment-related components may have contributed to its limited performance. Further multicenter validation in pediatric cohorts with broader case-mix and treatment patterns is warranted. The exploratory phenotype-based model requires independent prospective validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.